Johnson & Johnson (JNJ) financials

Pharmaceuticals · NYSE · Health Care

$273.20 -0.73% Close Oct 30, 2026 Live

Johnson & Johnson revenue and earnings by year

Johnson & Johnson's revenue was $94.2 billion in the fiscal year to December 28, 2025, up 6.0% from the year before. Net income was $26.8 billion, 28.5% of revenue. Since the fiscal year to January 1, 2017, revenue has grown 3.1% a year on average.

RevenueNet income
$25.0B$50.0B$75.0B
2017201720182019202120222023202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 10 fiscal years

In billions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Jan 2023Jan 2022Jan 2021Dec 2019Dec 2018Dec 2017Jan 2017
Revenue94.288.885.280.078.782.682.181.676.571.9
Revenue growth6.0%4.3%6.5%1.6%-4.7%0.6%0.6%6.7%6.3%—
Gross profit63.961.458.655.455.354.254.554.551.050.1
Gross margin67.9%69.1%68.8%69.3%70.3%65.6%66.4%66.8%66.7%69.7%
Operating income25.320.821.220.019.819.519.819.818.220.4
Operating margin26.8%23.4%24.9%24.9%25.2%23.6%24.1%24.3%23.8%28.3%
Net income26.814.135.217.920.914.715.115.31.316.5
Net margin28.5%15.8%41.3%22.4%26.5%17.8%18.4%18.8%1.7%23.0%
Diluted EPS$11.03$5.79$13.81$6.74$7.81$5.51$5.63$5.61$0.39$5.93
Free cash flow19.719.818.217.219.820.219.918.517.815.5

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open JNJ in Markets.

See also: JNJ valuation and P/E history · JNJ returns

No forecast, no recommendation. This page describes Johnson & Johnson from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.